Eli Lilly and Company (BIT:1LLY)
Italy · Delayed Price · Currency is EUR | Market Cap | 738.65B +14.1% |
| Revenue (ttm) | 62.66B +47.4% |
| Net Income | 21.92B +127.6% |
| EPS | 24.42 +129.1% |
| Shares Out | n/a |
| PE Ratio | 33.69 |
| Forward PE | 26.18 |
| Dividend | 3.91 (0.47%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 262 |
| Average Volume | 599 |
| Open | 841.20 |
| Previous Close | 843.50 |
| Day's Range | 829.50 - 841.20 |
| 52-Week Range | 535.20 - 972.00 |
| Beta | n/a |
| RSI | 57.20 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Novo and Lilly gain on signs weight-loss pills could expand the market
Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pricin...
Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.
While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.
Lilly commits additional $4.5 billion across Indiana manufacturing sites
Eli Lilly said on Wednesday it would commit an additional $4.5 billion investment across two of its three sites in Indiana, bringing the company's total capital expansion commitments in the...
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
Lilly's capital commitments to expand manufacturing in its home state now total $21 billion since 2020 Lilly Lebanon Advanced Therapies opens as company's first dedicated genetic medicine manufacturin...
Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly.
Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.
The Billion-Dollar Women's Health Market Driving A New Endometriosis Focus
The commercial success of GLP-1 therapies has reshaped the economics of modern pharmaceuticals. What began as a treatment pathway for type 2 diabetes and obesity has evolved into one of the most lucra...
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease clearance is a high clinical bar in UC requiring ...
Lilly declares second-quarter 2026 dividend
INDIANAPOLIS, May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common st...
FDA Reports Liver Failure in Patient Taking Lilly's Foundayo
The Food and Drug Administration has recorded two ‘serious' cases in patients taking Eli Lilly's weight-loss pill.
Eli Lilly and Company Transcript: AGM 2026
The meeting covered director elections, management and shareholder proposals, and strong financial results, including a 45% revenue increase and major product launches. Shareholder proposals on board independence and lobbying transparency did not pass. Dividend growth and manufacturing expansion were highlighted.
'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds
For the first time in 16 years, oncology is no longer the largest contributor to late-stage pipeline value, Deloitte has found. Pharma R&D returns for the world's top 20 pharma companies have improved...
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Lilly's obesity pill hits 5,612 prescriptions in third week after launch
Eli Lilly's newly launched oral weight loss drug was prescribed 5,612 times in the U.S. in the third week after its launch, according to analysts citing IQVIA data.
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand
Eli Lilly and Co. (NYSE:LLY) stock is trading higher after the weight loss drug giant released better-than-expected first quarter 2026 earnings and raised fiscal 2026 guidance.
Demand for Weight-Loss Drugs Drove Blockbuster Results for Eli Lilly. Its Stock Is Surging.
Eli Lilly's stock is powering higher on fresh signs of booming demand for its weight-loss drugs. Will it be enough to drive a recovery for the stock?
Eli Lilly CEO on new GLP-1 pill: It's been out 20 days and we have over 20,000 patients
More than 20,000 people have started taking Eli Lilly's GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday.
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
The Food and Drug Administration proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's blockbuster obesity and diabetes medications from the list of drugs that outsourcing fa...
QCOM Rally, RCL Regains Bookings Pace, LLY Soars
While Mag 7 names take a lot of the headlines after earnings, the moves from Qualcomm (QCOM), Royal Caribbean (RCL) and Eli Lilly (LLY) are on Diane King Hall's radar following Thursday's open. She br...
Eli Lilly and Company Earnings Call Transcript: Q1 2026
Q1 2026 saw 56% revenue growth, strong launches (notably Foundayo), and robust pipeline progress, with full-year guidance raised to $82–$85 billion. Key products and international expansion drove results, while new access programs and acquisitions support future growth.
US FDA proposes excluding weight-loss drugs from compounding list
The U.S. Food and Drug Administration on Thursday proposed excluding active ingredients for Novo Nordisk and Eli Lilly's weight-loss drugs on the list of drugs outsourcing facilities can use for c...
More than 20,000 people are taking Eli Lilly's weight loss pill, CEO says
More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo in the first few weeks after its launch, CEO Dave Ricks said. The FDA approved Lilly's once-daily pill Foundayo earlier this mo...
Eli Lilly cemented its lead in the booming weight-loss drug market with huge sales gains for the first quarter, as focus shifts to new pills
Consumer demand for blockbusters Mounjaro and Zepbound helped offset declining prices for the drugs.
Eli Lilly stock jumps 6% after strong earnings and raised guidance
Eli Lilly reported stronger-than-expected first-quarter earnings and revenue on Thursday, driven by robust demand for its blockbuster weight-loss and diabetes drugs, prompting the company to raise its...
Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket
Revenue tied to Lilly's Zepbound and Mounjaro more than doubles from the same period last year.
Lilly's stock rallies as sales of GLP-1 drugs nearly double
Eli Lilly's GLP-1 franchise brought in a total of $12.9 billion in sales in the first quarter as demand continued to soar for the drugs commonly used for weight loss.